Fujian Cancer Hospital

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests when to add the immunotherapy drug toripalimab to standard chemotherapy for people with advanced nasopharyngeal cancer. About 198 participants will get chemo on different days (Day 1, 5, or 9) to see which timing works best. The goal is to shrink tumors more effe…

This study tests whether it is safe to skip radiation to a specific neck area (Level Va) in patients with a type of throat cancer called nasopharyngeal carcinoma. About 474 newly diagnosed patients without cancer spread will be randomly assigned to standard radiation or a reduced…

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can improve outcomes for people with a rare type of esophageal cancer (small cell carcinoma) that hasn't spread far. About 15 adults will receive the combination treatment, and researcher…

This study tests whether adding two targeted drugs (sintilimab and nimotuzumab) to standard chemotherapy can help people with advanced head and neck cancer. The goal is to shrink tumors enough to avoid removing the voice box. About 23 adults with EGFR-positive, stage III-IVB head…

This study tests whether combining targeted radiation (SBRT) with two drugs, anlotinib and bimepolizumab, can shrink tumors in people with advanced kidney cancer that cannot be surgically removed. About 27 adults aged 18-80 with clear cell or papillary kidney cancer will receive …

This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to chemotherapy before standard chemoradiation can help people with locally advanced cervical cancer live longer without the disease getting worse. About 486 adults aged 18-75 with stage III-IV…

This study tests a drug called hetrombopag to see if it can prevent or reduce low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. The trial will include 72 adults aged 18-75. Researchers will measure how many patients develop severe…

This study tests if a shorter course of radiation combined with chemotherapy and an immunotherapy drug (tislelizumab) works as well as the standard longer radiation plus the same immunotherapy for people with locally advanced rectal cancer. The main goal is to see how many patien…

This study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial treatment. First, patients receive a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then, they take a chemotherapy pill (capecitabine) with the immunothera…

This study tests whether a cream called triethanolamine can prevent or treat vaginal irritation caused by radiation therapy in cervical cancer patients. About 238 women will either use the cream daily plus standard care, or standard care alone, from the start of radiation until 2…

This study looks at whether a skin test can help predict severe allergic reactions to the chemotherapy drug oxaliplatin. About 380 cancer patients will receive a tiny injection of the drug under the skin before their regular treatment. Researchers will track who develops a rash o…

This study looks at two different treatment plans for people with a type of throat cancer (nasopharyngeal carcinoma) whose tumors did not shrink after two rounds of chemotherapy. One plan gives more chemotherapy before radiation, while the other goes straight to radiation. The go…